Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Boston Scientific Corp., profitability ratios (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Return on Sales
Gross profit margin 69.03% 68.81% 68.83% 68.87% 68.99% 68.78% 67.41% 66.89% 64.90% 65.05% 67.20% 68.26% 70.41% 70.98% 71.20% 71.33% 71.12% 71.37%
Operating profit margin 13.30% 13.00% 11.36% 11.81% 10.65% 10.09% 9.32% 4.26% 1.42% -0.81% 0.79% 6.58% 10.41% 14.14% 15.66% 16.19% 16.50% 15.33%
Net profit margin 6.91% 5.50% 5.20% 7.17% 6.66% 8.76% 10.07% 5.19% 2.45% -0.83% 36.65% 39.24% 39.75% 43.78% 10.49% 13.85% 18.08% 17.01%
Return on Investment
Return on equity (ROE) 5.05% 3.97% 3.70% 5.12% 4.84% 6.26% 7.02% 3.64% 1.58% -0.54% 23.80% 25.53% 31.06% 33.87% 11.24% 14.81% 19.46% 19.15%
Return on assets (ROA) 2.74% 2.15% 2.04% 2.75% 2.50% 3.23% 3.62% 1.86% 0.80% -0.27% 12.01% 12.93% 14.24% 15.38% 4.07% 5.74% 7.55% 7.96%

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Boston Scientific Corp. gross profit margin ratio deteriorated from Q3 2022 to Q4 2022 but then improved from Q4 2022 to Q1 2023 exceeding Q3 2022 level.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Boston Scientific Corp. operating profit margin ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Boston Scientific Corp. net profit margin ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Boston Scientific Corp. ROE improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.
ROA A profitability ratio calculated as net income divided by total assets. Boston Scientific Corp. ROA improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.

Gross Profit Margin

Boston Scientific Corp., gross profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Gross profit 2,349 2,232 2,191 2,233 2,071 2,155 2,032 2,132 1,858 1,709 1,790 1,212 1,737 2,054 1,930 1,873 1,763 1,833 1,720 1,751 1,707
Net sales 3,389 3,242 3,170 3,244 3,026 3,127 2,932 3,077 2,752 2,708 2,659 2,003 2,543 2,904 2,707 2,631 2,493 2,561 2,393 2,490 2,379
Profitability Ratio
Gross profit margin1 69.03% 68.81% 68.83% 68.87% 68.99% 68.78% 67.41% 66.89% 64.90% 65.05% 67.20% 68.26% 70.41% 70.98% 71.20% 71.33% 71.12% 71.37%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 50.66% 51.54% 52.60% 53.54% 52.44% 52.21% 52.01% 50.69% 51.25% 50.49% 50.18% 50.97% 52.13% 52.46%
Cigna Group 12.39% 12.44% 12.39% 12.40% 12.30% 12.41% 12.77% 13.13% 14.04% 14.43% 15.05% 15.49% 15.30% 15.57%
CVS Health Corp. 16.16% 16.62% 16.94% 17.12% 17.35% 17.48% 17.35% 17.43% 17.99% 18.01% 18.10% 18.16% 17.51% 17.41%
Elevance Health Inc. 16.90% 16.79% 16.85% 16.79% 16.89% 17.09% 17.30% 17.57% 19.38% 19.71% 20.18% 20.43% 18.70% 18.77%
Intuitive Surgical Inc. 66.86% 67.44% 67.77% 68.16% 68.84% 69.32% 69.12% 68.69% 66.48% 65.65% 66.44% 67.07% 69.04% 69.45%
Medtronic PLC 67.61% 67.98% 67.89% 67.39% 66.53% 65.19% 63.85% 64.57% 65.76% 67.41% 68.96% 69.22% 69.62% 70.04%
UnitedHealth Group Inc. 24.20% 24.09% 23.74% 23.51% 23.31% 23.60% 23.75% 23.80% 25.79% 25.62% 25.83% 25.95% 23.52% 23.19%

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
Gross profit margin = 100 × (Gross profitQ1 2023 + Gross profitQ4 2022 + Gross profitQ3 2022 + Gross profitQ2 2022) ÷ (Net salesQ1 2023 + Net salesQ4 2022 + Net salesQ3 2022 + Net salesQ2 2022)
= 100 × (2,349 + 2,232 + 2,191 + 2,233) ÷ (3,389 + 3,242 + 3,170 + 3,244) = 69.03%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Boston Scientific Corp. gross profit margin ratio deteriorated from Q3 2022 to Q4 2022 but then improved from Q4 2022 to Q1 2023 exceeding Q3 2022 level.

Operating Profit Margin

Boston Scientific Corp., operating profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Operating income (loss) 552 402 358 423 466 180 387 262 370 50 (205) (71) 146 210 383 384 541 319 388 392 407
Net sales 3,389 3,242 3,170 3,244 3,026 3,127 2,932 3,077 2,752 2,708 2,659 2,003 2,543 2,904 2,707 2,631 2,493 2,561 2,393 2,490 2,379
Profitability Ratio
Operating profit margin1 13.30% 13.00% 11.36% 11.81% 10.65% 10.09% 9.32% 4.26% 1.42% -0.81% 0.79% 6.58% 10.41% 14.14% 15.66% 16.19% 16.50% 15.33%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 16.77% 19.16% 20.95% 22.42% 20.73% 19.56% 20.04% 18.46% 17.97% 15.48% 13.39% 12.78% 14.18% 14.21%
Cigna Group 4.54% 4.69% 4.59% 4.71% 4.64% 4.60% 4.59% 4.57% 4.98% 5.12% 5.37% 5.47% 5.18% 5.31%
CVS Health Corp. 2.33% 2.41% 2.02% 4.35% 4.39% 4.54% 4.75% 4.93% 5.19% 5.19% 5.44% 5.36% 4.89% 4.69%
Elevance Health Inc. 4.99% 4.94% 5.01% 5.07% 5.10% 5.15% 4.91% 3.68% 4.83% 4.97% 5.59% 6.99% 5.47% 5.49%
Humana Inc. 4.45% 4.11% 4.09% 3.57% 3.73% 3.80% 3.40% 4.97% 6.60% 6.56% 7.77% 6.77% 5.09% 4.96%
Intuitive Surgical Inc. 24.21% 25.35% 27.05% 28.48% 30.69% 31.89% 32.55% 31.27% 26.01% 24.09% 23.95% 25.86% 30.52% 30.69%
Medtronic PLC 19.37% 18.15% 17.89% 16.68% 14.78% 14.89% 11.44% 12.77% 14.25% 16.57% 20.67% 20.47% 21.25% 20.51%
UnitedHealth Group Inc. 8.87% 8.83% 8.65% 8.32% 8.19% 8.40% 7.91% 7.73% 9.24% 8.76% 9.55% 9.89% 8.12% 8.19%

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
Operating profit margin = 100 × (Operating income (loss)Q1 2023 + Operating income (loss)Q4 2022 + Operating income (loss)Q3 2022 + Operating income (loss)Q2 2022) ÷ (Net salesQ1 2023 + Net salesQ4 2022 + Net salesQ3 2022 + Net salesQ2 2022)
= 100 × (552 + 402 + 358 + 423) ÷ (3,389 + 3,242 + 3,170 + 3,244) = 13.30%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Boston Scientific Corp. operating profit margin ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.

Net Profit Margin

Boston Scientific Corp., net profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Net income (loss) 314 140 188 260 110 95 419 186 341 209 (155) (147) 11 3,996 126 154 424 386 432 555 298
Net sales 3,389 3,242 3,170 3,244 3,026 3,127 2,932 3,077 2,752 2,708 2,659 2,003 2,543 2,904 2,707 2,631 2,493 2,561 2,393 2,490 2,379
Profitability Ratio
Net profit margin1 6.91% 5.50% 5.20% 7.17% 6.66% 8.76% 10.07% 5.19% 2.45% -0.83% 36.65% 39.24% 39.75% 43.78% 10.49% 13.85% 18.08% 17.01%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 13.98% 15.88% 17.52% 18.78% 17.35% 16.42% 17.12% 15.85% 15.33% 12.99% 10.50% 9.89% 11.15% 11.56%
Cigna Group 3.71% 3.72% 3.69% 3.08% 3.07% 3.11% 4.97% 4.93% 5.22% 5.31% 3.40% 3.43% 3.22% 3.35%
CVS Health Corp. 1.20% 1.29% 1.00% 2.66% 2.68% 2.72% 2.67% 2.60% 2.74% 2.68% 3.00% 3.14% 2.77% 2.59%
Elevance Health Inc. 3.89% 3.87% 4.09% 4.13% 4.37% 4.46% 4.17% 3.32% 3.82% 3.78% 4.26% 5.27% 4.42% 4.66%
Humana Inc. 3.28% 3.03% 3.07% 3.52% 3.52% 3.54% 3.31% 3.13% 4.78% 4.43% 5.67% 5.00% 3.89% 4.20%
Intuitive Surgical Inc. 20.40% 21.25% 22.52% 24.05% 27.84% 29.85% 30.78% 31.43% 25.78% 24.33% 24.45% 26.07% 30.11% 30.80%
Medtronic PLC 16.75% 15.90% 15.46% 14.79% 12.29% 11.97% 10.36% 12.69% 15.80% 16.56% 17.11% 15.11% 14.41% 15.16%
UnitedHealth Group Inc. 6.21% 6.25% 6.21% 5.99% 5.91% 6.06% 5.56% 5.37% 6.46% 6.03% 6.66% 6.94% 5.63% 5.76%

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
Net profit margin = 100 × (Net income (loss)Q1 2023 + Net income (loss)Q4 2022 + Net income (loss)Q3 2022 + Net income (loss)Q2 2022) ÷ (Net salesQ1 2023 + Net salesQ4 2022 + Net salesQ3 2022 + Net salesQ2 2022)
= 100 × (314 + 140 + 188 + 260) ÷ (3,389 + 3,242 + 3,170 + 3,244) = 6.91%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Boston Scientific Corp. net profit margin ratio improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.

Return on Equity (ROE)

Boston Scientific Corp., ROE calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Net income (loss) 314 140 188 260 110 95 419 186 341 209 (155) (147) 11 3,996 126 154 424 386 432 555 298
Stockholders’ equity 17,850 17,573 17,640 17,251 16,735 16,622 16,461 15,942 15,719 15,326 15,564 15,616 13,804 13,877 9,699 9,425 9,233 8,726 8,289 7,744 7,030
Profitability Ratio
ROE1 5.05% 3.97% 3.70% 5.12% 4.84% 6.26% 7.02% 3.64% 1.58% -0.54% 23.80% 25.53% 31.06% 33.87% 11.24% 14.81% 19.46% 19.15%
Benchmarks
ROE, Competitors2
Abbott Laboratories 15.68% 18.90% 22.11% 23.44% 21.82% 19.75% 21.04% 18.86% 17.06% 13.71% 10.78% 10.17% 11.84% 11.86%
Cigna Group 15.17% 14.86% 14.69% 11.94% 11.69% 11.39% 17.68% 16.73% 17.52% 16.81% 11.03% 11.11% 10.91% 11.26%
CVS Health Corp. 5.57% 5.84% 4.46% 10.86% 10.83% 10.54% 10.20% 9.83% 10.44% 10.35% 11.56% 12.14% 11.08% 10.39%
Elevance Health Inc. 16.62% 16.59% 17.26% 17.04% 17.36% 16.93% 15.44% 12.10% 13.92% 13.77% 14.61% 17.17% 15.08% 15.15%
Humana Inc. 18.79% 18.33% 17.27% 20.29% 19.81% 18.24% 16.44% 16.72% 26.23% 24.53% 26.34% 24.29% 21.16% 22.49%
Intuitive Surgical Inc. 11.70% 11.98% 11.97% 11.93% 13.58% 14.32% 14.80% 14.97% 11.56% 10.90% 11.38% 13.00% 16.30% 16.69%
Medtronic PLC 9.88% 9.59% 9.35% 9.05% 7.54% 7.01% 5.70% 7.05% 8.77% 9.44% 10.26% 9.23% 8.78% 9.25%
UnitedHealth Group Inc. 25.46% 25.87% 26.03% 25.07% 23.98% 24.09% 21.95% 21.03% 25.42% 23.52% 25.65% 26.87% 24.14% 24.02%

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
ROE = 100 × (Net income (loss)Q1 2023 + Net income (loss)Q4 2022 + Net income (loss)Q3 2022 + Net income (loss)Q2 2022) ÷ Stockholders’ equity
= 100 × (314 + 140 + 188 + 260) ÷ 17,850 = 5.05%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Boston Scientific Corp. ROE improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.

Return on Assets (ROA)

Boston Scientific Corp., ROA calculation (quarterly data)

Microsoft Excel
Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Net income (loss) 314 140 188 260 110 95 419 186 341 209 (155) (147) 11 3,996 126 154 424 386 432 555 298
Total assets 32,892 32,469 31,947 32,189 32,337 32,229 31,877 31,168 30,900 30,777 30,845 30,823 30,113 30,565 26,756 24,309 23,802 20,999 20,379 19,615 19,202
Profitability Ratio
ROA1 2.74% 2.15% 2.04% 2.75% 2.50% 3.23% 3.62% 1.86% 0.80% -0.27% 12.01% 12.93% 14.24% 15.38% 4.07% 5.74% 7.55% 7.96%
Benchmarks
ROA, Competitors2
Abbott Laboratories 7.87% 9.31% 10.84% 11.53% 10.44% 9.40% 9.82% 8.70% 7.86% 6.20% 4.90% 4.52% 5.36% 5.43%
Cigna Group 4.56% 4.63% 4.59% 3.59% 3.53% 3.46% 5.44% 5.29% 5.55% 5.44% 3.31% 3.30% 3.18% 3.28%
CVS Health Corp. 1.66% 1.82% 1.36% 3.55% 3.43% 3.39% 3.23% 3.12% 3.22% 3.11% 3.41% 3.51% 3.13% 2.98%
Elevance Health Inc. 5.69% 5.86% 6.03% 6.05% 6.21% 6.26% 5.63% 4.40% 4.93% 5.28% 5.72% 6.72% 5.80% 6.21%
Humana Inc. 5.69% 6.52% 5.53% 6.71% 6.55% 6.61% 5.90% 6.52% 9.95% 9.63% 10.79% 9.11% 7.55% 9.31%
Intuitive Surgical Inc. 10.05% 10.19% 10.39% 10.47% 12.02% 12.58% 13.06% 13.20% 10.17% 9.50% 9.92% 11.24% 14.02% 14.17%
Medtronic PLC 5.79% 5.54% 5.35% 5.13% 4.23% 3.87% 2.97% 3.69% 4.70% 5.28% 5.73% 5.13% 4.84% 5.16%
UnitedHealth Group Inc. 7.30% 8.19% 7.99% 7.93% 7.89% 8.15% 7.24% 6.90% 8.23% 7.81% 8.76% 8.88% 7.27% 7.96%

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q1 2023 Calculation
ROA = 100 × (Net income (loss)Q1 2023 + Net income (loss)Q4 2022 + Net income (loss)Q3 2022 + Net income (loss)Q2 2022) ÷ Total assets
= 100 × (314 + 140 + 188 + 260) ÷ 32,892 = 2.74%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Boston Scientific Corp. ROA improved from Q3 2022 to Q4 2022 and from Q4 2022 to Q1 2023.